Amgen drug under FDA review in wake of 8 deaths
The FDA has linked Amgen’s vasculitis drug Tavneos to 76 postmarketing cases of drug-induced liver injury, including eight deaths, 54 hospitalizations and 74 serious outcomes. Seven patients developed vanishing bile duct syndrome, three of whom died. The medication, approved in October 2021, is used to treat severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis. Most cases showed […]
Continue Reading